Home/Pipeline/SECUADO

SECUADO

Schizophrenia

ApprovedActive

Key Facts

Indication

Schizophrenia

Phase

Approved

Status

Active

Company

Noven Pharmaceuticals

About Noven Pharmaceuticals

Noven Pharmaceuticals is a U.S.-based, commercial-stage specialty pharma company with a core competency in transdermal patch technology. Founded in 1989, the company has a portfolio of marketed products for ADHD, schizophrenia, and menopausal hormone therapy, leveraging its fully integrated capabilities from R&D to sales. As a wholly-owned subsidiary of Hisamitsu, Noven benefits from deep transdermal expertise and manufacturing scale while focusing on niche CNS and women's health markets. Its strategy combines internal development with strategic partnerships to expand its product offerings.

View full company profile

Therapeutic Areas

Mental Health Women's Health

Other Schizophrenia Drugs

Drug	Company	Phase	Status
DB103 (Pomaglumetad)	Denovo Biopharma	Phase 2b/3	Active
ZZ6398	Zhongze Therapeutics	Phase 1/2	Active
RBP-7000 (PERSERIS®)	Indivior	Marketed	Commercial
Undisclosed Programs	johnson-and-johnson-innovative-medicine	Pipeline	Active
Schizophrenia Candidate	Teva	Phase 3	Active
Schizophrenia Model Service	NeuroProof	Pre-clinical	Active
LYN-005 (Nortiva)	Lyndra	Phase 3	Active
TerXT	Terran Biosciences	Late-stage (Pre-Phase 3)	Active
Undisclosed Program	Curemark	Preclinical	Active
Schizophrenia Intermediate	OFD Biopharma	Proof of concept	Active
Schizophrenia	Keltic Pharma Therapeutics	Pre-clinical	Active
AVAT-031	Avata Biosciences	Discovery	Active